peterschreiber.media Wolfe Research started coverage of Akero Therapeutics ( NASDAQ: AKRO ) with an outperform rating, citing its drug candidate for the treatment of MASH, EFX. The investment firm said the stock's two major drivers were whether the launch of Madrigal’s ( MDGL ) Rezdiffra exceeds expectations and EFX succeeds clinically in the treatment of stage F4 liver fibrosis.
Wolfe said it was bullish on the Rezdiffra launch, adding Madrigal will be able to “prime the market for possible competitors like AKRO." The firm added that EFX has “modest odds of success in F4, but upside is greater than downside.” Wolfe set its price target for the stock at $40.
More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Seeking Alpha’s Quant Rating on Akero Therapeutics Historical earnings data for Akero Therapeutics Financial information for Akero Therapeutics.
